AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35187164 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) during the same virtual reality task, duration 10 minutes, sitting position.
Number of subjects: 0
Study 34318543 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat follow-up management
Number of subjects: 80
Study 34318543 — intervention group
Group type: COMPARATOR
Intervention: Traditional follow-up method
Number of subjects: 80
Study 32524158 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum urinary retention requiring indwelling catheterization
Number of subjects: 5802
Study 32524158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 5802
Study 32524158 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 2nd-degree obstetrical laceration
Number of subjects: 5802
Study 32524158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization during labor
Number of subjects: 5802
Study 35685406 — intervention group
Group type: EXPERIMENTAL
Intervention: hUC-MSCs-CM via MN
Number of subjects: 30
Study 35685406 — intervention group
Group type: COMPARATOR
Intervention: MN saline
Number of subjects: 30
Study 33300592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed music group
Number of subjects: 0
Study 33300592 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music group
Number of subjects: 0
Study 33300592 — intervention group
Group type: COMPARATOR
Intervention: No-music group
Number of subjects: 0
Study 34496116 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond Nd:YAG laser treatment
Number of subjects: 63
Study 33003548 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet plus 250 min of exercise per week
Number of subjects: 125
Study 33003548 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet plus 150 min of moderate intensity exercise per week
Number of subjects: 125
Study 33003548 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet alone
Number of subjects: 125
Study 33003548 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (energy-restricted diet alone, diet plus 150 min exercise, diet plus 250 min exercise)
Number of subjects: 125
Study 37753690 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide-containing body emollients alone (T1)
Number of subjects: 122
Study 37753690 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide-containing body emollients plus cleansing gel (T2)
Number of subjects: 122
Study 37753690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 37753690 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide-containing body emollients (T1)
Number of subjects: 122
Study 33373078 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME™)
Number of subjects: 0
Study 33373078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35551078 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Disease Management (IDM)
Number of subjects: 280
Study 35551078 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 280
Study 33148427 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus‐eluting stents (SES)
Number of subjects: 1134
Study 33148427 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy everolimus‐eluting stents (EES)
Number of subjects: 1134
Study 33148427 — intervention group
Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stents (RI-ZES)
Number of subjects: 1134
Study 33148427 — intervention group
Group type: COMPARATOR
Intervention: Resolute Onyx zotarolimus‐eluting stents (RO-ZES)
Number of subjects: 1134
Study 32987917 — intervention group
Group type: EXPERIMENTAL
Intervention: Abscisic acid (ABA) treatment for 3 months
Number of subjects: 65
Study 32987917 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 3 months
Number of subjects: 65
Study 33690962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion marginal zone image
Number of subjects: 479
Study 33690962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion inner region image
Number of subjects: 479
Study 33690962 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior echo region image
Number of subjects: 479
Study 33690962 — intervention group
Group type: EXPERIMENTAL
Intervention: Original image
Number of subjects: 479
Study 33690962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion of all four types of deep features (original image + three discriminative region images)
Number of subjects: 479
Study 34438242 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1044457 in CMPK1
Number of subjects: 91
Study 34438242 — intervention group
Group type: EXPERIMENTAL
Intervention: rs693955 in SLC29A1
Number of subjects: 91
Study 34438242 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2807312 in TLE4
Number of subjects: 91
Study 34438242 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-gene model analysis
Number of subjects: 91
Study 32798050 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light label (TL)
Number of subjects: 357
Study 32798050 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR)
Number of subjects: 357
Study 32798050 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline Daily Amounts (%GDA)
Number of subjects: 357
Study 32798050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score (NS)
Number of subjects: 357
Study 32798050 — intervention group
Group type: COMPARATOR
Intervention: No-nutritional label (control)
Number of subjects: 357
Study 34191259 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for ACS
Number of subjects: 877
Study 34191259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant bleeding events
Number of subjects: 877
Study 32243009 — intervention group
Group type: EXPERIMENTAL
Intervention: VasH300 (300 mg CWE/day, n = 32)
Number of subjects: 96
Study 32243009 — intervention group
Group type: EXPERIMENTAL
Intervention: VasH600 (600 mg CWE/day, n = 32)
Number of subjects: 96
Study 32243009 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 96
Study 35227197 — intervention group
Group type: EXPERIMENTAL
Intervention: Advisory display SmartPilot® View (SPV)
Number of subjects: 114
Study 35227197 — intervention group
Group type: COMPARATOR
Intervention: Current standards
Number of subjects: 114
Study 33207093 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 84
Study 33207093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 36113537 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg bulevirtide with tenofovir disoproxil fumarate (TDF)
Number of subjects: 120
Study 36113537 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bulevirtide with TDF
Number of subjects: 120
Study 36113537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bulevirtide with TDF
Number of subjects: 120
Study 36113537 — intervention group
Group type: COMPARATOR
Intervention: TDF alone
Number of subjects: 120
Study 33768641 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin protection products (various formulations)
Number of subjects: 6
Study 33768641 — intervention group
Group type: COMPARATOR
Intervention: Control (no skin protection product)
Number of subjects: 6
Study 32746923 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 0
Study 34433517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment
Number of subjects: 86
Study 34433517 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 86
Study 32932257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 290
Study 35093646 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric bootstrap (PB) method
Number of subjects: 400
Study 35093646 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear mixed model with random intercept for clusters
Number of subjects: 400
Study 33009690 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly video consultations as an add-on to regular care
Number of subjects: 240
Study 33009690 — intervention group
Group type: COMPARATOR
Intervention: Regular care (waitlist-control group)
Number of subjects: 240
Study 36171584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports (Goalball, Football 5-a-side, Martial Arts)
Number of subjects: 0
Study 36171584 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training (Bodyweight exercises)
Number of subjects: 0
Study 36171584 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 0
Study 36171584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports and functional training
Number of subjects: 0
Study 32493441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100mg daily subcutaneous injection for up to 28 days)
Number of subjects: 342
Study 32493441 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab (11mg/kg single intravenous injection)
Number of subjects: 342
Study 32493441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8mg/kg single intravenous injection, max 800mg)
Number of subjects: 342
Study 32493441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra and Siltuximab (combination treatment)
Number of subjects: 342
Study 32493441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra and Tocilizumab (combination treatment)
Number of subjects: 342
Study 32493441 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 342
Study 36018219 — intervention group
Group type: EXPERIMENTAL
Intervention: Test eldecalcitol soft capsules
Number of subjects: 58
Study 36018219 — intervention group
Group type: COMPARATOR
Intervention: Reference eldecalcitol soft capsules
Number of subjects: 58
Study 36318438 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga based Cardiac Rehabilitation
Number of subjects: 80
Study 36318438 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 80
Study 33883411 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D limb volume ultrasound combined with fetal abdominal circumference measurement
Number of subjects: 202
Study 33883411 — intervention group
Group type: COMPARATOR
Intervention: Traditional formulas (Hadlock, Lee2009, INTERGROWTH-21st)
Number of subjects: 202
Study 32672829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma (CAP) therapy
Number of subjects: 45
Study 32672829 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study 36027496 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl supplementation (24mmol thrice daily for 5 days)
Number of subjects: 18
Study 36027496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 32950072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day)
Number of subjects: 16703
Study 32950072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16703
Study 35279527 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus etoposide plus cisplatin or carboplatin (EP)
Number of subjects: 805
Study 35279527 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab plus etoposide plus cisplatin or carboplatin (EP)
Number of subjects: 805
Study 35279527 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin or carboplatin (EP)
Number of subjects: 805
Study 33640203 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic enrichment analysis for ALS conditional on body mass index, body fat percentage, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and type 2 diabetes.
Number of subjects: 0
Study 33640203 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of shared genetic loci between ALS and obesity-related traits.
Number of subjects: 0
Study 33640203 — intervention group
Group type: EXPERIMENTAL
Intervention: GGNBP2 identified as a novel ALS risk gene.
Number of subjects: 0
Study 33640203 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional enrichment analysis of shared risk genes.
Number of subjects: 0
Study 32171877 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 120
Study 32171877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine digluconate (CHX)
Number of subjects: 120
Study 32171877 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 120
Study 32171877 — intervention group
Group type: COMPARATOR
Intervention: MTA Fillapex
Number of subjects: 120
Study 32171877 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (regardless of irrigation protocol and sealer)
Number of subjects: 120
Study 32171877 — intervention group
Group type: COMPARATOR
Intervention: Laser therapies (PBT and PDT)
Number of subjects: 120
Study 616173496 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g/day n3-PUFA
Number of subjects: 43
Study 616173496 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g/day n3-PUFA
Number of subjects: 43
Study 616173496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 34927469 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-reperfusion time
Number of subjects: 2855
Study 34927469 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA-to-groin time
Number of subjects: 2855
Study 34927469 — intervention group
Group type: EXPERIMENTAL
Intervention: Groin-to-reperfusion time
Number of subjects: 2855
Study 32827656 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged in end-of-life discussions (EOLD)
Number of subjects: 836
Study 32827656 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of caring for a loved one
Number of subjects: 836
Study 32827656 — intervention group
Group type: COMPARATOR
Intervention: Experience of the death of a loved one
Number of subjects: 836
Study 33092653 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg nanomicelles containing curcumin, four times per day for two weeks
Number of subjects: 40
Study 33092653 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules with the same appearance and characteristics, four times per day for two weeks
Number of subjects: 40
Study 33092653 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg nanomicelles containing curcumin
Number of subjects: 40
Study 33092653 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 40
Study 35239682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 150
Study 35239682 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 150
Study 32387055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (PRN dosing schedule)
Number of subjects: 943
Study 32387055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly dosing schedule)
Number of subjects: 943
Study 36125830 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose immunosuppression
Number of subjects: 0
Study 36125830 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34388007 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy
Number of subjects: 144
Study 35499570 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear Pedagogy (NLP)
Number of subjects: 16
Study 35499570 — intervention group
Group type: COMPARATOR
Intervention: Linear Pedagogy (LP)
Number of subjects: 16
Study 34797697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologic home-hospitalization (OHH)
Number of subjects: 148
Study 34797697 — intervention group
Group type: EXPERIMENTAL
Intervention: Full OHH
Number of subjects: 148
Study 34797697 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial OHH
Number of subjects: 148
Study 34797697 — intervention group
Group type: COMPARATOR
Intervention: Standard ambulatory cancer care (SOC)
Number of subjects: 148
Study 32031651 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin initiation
Number of subjects: 7034
Study 32031651 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin initiation (eligible participants)
Number of subjects: 7034
Study 32031651 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin initiation (ineligible participants)
Number of subjects: 7034
Study 35248268 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (4 sessions)
Number of subjects: 32
Study 35248268 — intervention group
Group type: COMPARATOR
Intervention: Electrotherapy (10 sessions)
Number of subjects: 32
Study 34531304 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 0
Study 35351253 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 40
Study 35351253 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study 34245652 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 270
Study 34245652 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation (EA)
Number of subjects: 270
Study 34750933 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (NB-UVB, fractional CO2 laser, topical bimatoprost 0.01%)
Number of subjects: 15
Study 34750933 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (NB-UVB, fractional CO2 laser)
Number of subjects: 15
Study 34501274 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercise program
Number of subjects: 141
Study 34501274 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for well-being
Number of subjects: 141
Study 34501274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 35500968 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory kinesiology tape (applied from origin to insertion)
Number of subjects: 39
Study 35500968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory kinesiology tape (applied from insertion to origin)
Number of subjects: 39
Study 35500968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 32041744 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation in hum-ob mice on a high-fat diet
Number of subjects: 4
Study 32041744 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation in obese individuals
Number of subjects: 4
Study 33530701 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention including facilitated conversation and advance directive completion
Number of subjects: 449
Study 33530701 — intervention group
Group type: COMPARATOR
Intervention: Control group including Developmental/relationship history and Nutrition/Exercise
Number of subjects: 449
Study 33530701 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 449
Study 33127015 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate magnetic resonance imaging (MRI)
Number of subjects: 0
Study 33127015 — intervention group
Group type: COMPARATOR
Intervention: Standard care with radiographs only
Number of subjects: 0
Study 36112377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cut mesh procedure
Number of subjects: 336
Study 36112377 — intervention group
Group type: COMPARATOR
Intervention: Mesh-kit procedure
Number of subjects: 336
Study 32384142 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-Negative Design (TND)
Number of subjects: 0
Study 32384142 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-Matched Design (FMD)
Number of subjects: 0
Study 33112245 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate interactivity (dropdown menus)
Number of subjects: 983
Study 33112245 — intervention group
Group type: EXPERIMENTAL
Intervention: High interactivity (dropdown menus and responsive infographics)
Number of subjects: 983
Study 33112245 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no interactive features)
Number of subjects: 983
Study 33112245 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate interactivity
Number of subjects: 983
Study 33112245 — intervention group
Group type: EXPERIMENTAL
Intervention: High interactivity
Number of subjects: 983
Study 35619813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab (LP)
Number of subjects: 0
Study 35619813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab (LP) in pMMR subgroup
Number of subjects: 0
Study 35619813 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 32178568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based combined intravenous and inhalation anesthesia (group S)
Number of subjects: 40
Study 32178568 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based total intravenous anesthesia (group P)
Number of subjects: 40
Study 35561632 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotionality (anxiety and depression symptoms, stress, negative affect)
Number of subjects: 73
Study 35561632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol craving
Number of subjects: 73
Study 34922494 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred and health-promoting intervention
Number of subjects: 81
Study 34922494 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 81
Study 35523498 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP levels individually adjusted according to driving pressure in addition to RM
Number of subjects: 680
Study 35523498 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP levels (≤5 cm H2O) without RM
Number of subjects: 680
Study 33588930 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual method of oral hygiene education
Number of subjects: 90
Study 33588930 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory method of oral hygiene education
Number of subjects: 90
Study 33588930 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic method of oral hygiene education
Number of subjects: 90
Study 35319853 — intervention group
Group type: EXPERIMENTAL
Intervention: BASKA mask
Number of subjects: 65
Study 35319853 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 65
Study 35939599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/day for 3 cycles)
Number of subjects: 323